Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Update

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 6,607 shares, a decrease of 50.9% from the August 31st total of 13,469 shares. Based on an average daily volume of 43,279 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.6% of the shares of the stock are sold short.

Regentis Biomaterials Price Performance

Shares of Regentis Biomaterials stock traded down $0.04 during trading on Wednesday, hitting $1.81. The stock had a trading volume of 22,185 shares, compared to its average volume of 1,859,494. Regentis Biomaterials has a 12 month low of $1.23 and a 12 month high of $15.50. The firm’s fifty day simple moving average is $1.96 and its 200-day simple moving average is $2.61.

Regentis Biomaterials (NYSEAMERICAN:RGNT) last issued its quarterly earnings data on Friday, September 11th. The company reported ($0.22) EPS for the quarter.

Institutional Investors Weigh In On Regentis Biomaterials

A hedge fund recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials as of its most recent filing with the SEC.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is an Israel-based medical device company developing biomaterial technologies for the treatment of cartilage injuries and other orthopedic conditions. The company focuses on regenerative solutions intended to support the repair of damaged tissue while reducing the need for more invasive procedures.

Its lead product is GelrinC, a synthetic, cell-free hydrogel implant designed for the treatment of focal cartilage defects in the knee. The product is placed arthroscopically and forms a scaffold intended to integrate with surrounding tissue and support the regeneration of hyaline-like cartilage.

Regentis Biomaterials operates as a clinical-stage company, with activities centered on product development, clinical evaluation, regulatory advancement and potential commercialization of its orthopedic biomaterial platform.